Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| sunitinib | PDGFRB | Direct | yes | 5 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | PDGFRB | Direct | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | PDGFRB | Direct | 4 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PDGFRB | Direct | 3 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | PDGFRB | Direct | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | PDGFRB | Direct | 2 | ||||||||
| nintedanib | PDGFRB | Direct | yes | 2 | |||||||
| nintedanib, pembrolizumab | PDGFRB | Direct | 2 | ||||||||
| pazopanib | PDGFRB | Direct | yes | 2 | |||||||
| regorafenib | PDGFRB | Direct | yes | 2 | |||||||
| regorafenib, laboratory biomarker analysis | PDGFRB | Direct | 2 | ||||||||
| sorafenib, administered orally, ct/mri | PDGFRB | Direct | 2 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | PDGFRB | Direct | 1 | ||||||||
| atezolizumab, tivozanib | PDGFRB | Direct | 1 | ||||||||
| bevacizumab, dasatinib, placebo | PDGFRB | Direct | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib | PDGFRB | Direct | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, erdafitinib, magnetic resonance imaging | PDGFRB | Direct | 1 | ||||||||
| biospecimen collection, erdafitinib, magnetic resonance imaging, optical coherence tomography | PDGFRB | Direct | 1 | ||||||||
| byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab | PDGFRB | Direct | 1 | ||||||||
| cisplatin, pemetrexed disodium, sorafenib | PDGFRB | Direct | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | PDGFRB | Direct | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | PDGFRB | Direct | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | PDGFRB | Direct | 1 | ||||||||
| dasatinib, mfolfox6 | PDGFRB | Direct | 1 | ||||||||
| dasatinib, pharmacological study | PDGFRB | Direct | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | PDGFRB | Direct | 1 | ||||||||
| erdafitinib | PDGFRB | Direct | 1 | ||||||||
| everolimus, sorafenib | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, erlotinib, sorafenib | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, placebo, sorafenib | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, sorafenib, radiotherapy | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff | PDGFRB | Direct | 1 | ||||||||
| gemcitabine, sunitinib | PDGFRB | Direct | 1 | ||||||||
| imatinib, irinotecan, carboplatin | PDGFRB | Direct | 1 | ||||||||
| lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil | PDGFRB | Direct | 1 | ||||||||
| oxaliplatin, sorafenib | PDGFRB | Direct | 1 | ||||||||
| pazopanib, 5-fu, oxaliplatin, leukovorin (flo) | PDGFRB | Direct | 1 | ||||||||
| pazopanib, lapatinib | PDGFRB | Direct | 1 | ||||||||
| pazopanib, placebo | PDGFRB | Direct | 1 | ||||||||
| pegilodecakin, paclitaxel or docetaxel and carboplatin or cisplatin, folfox (oxaliplatin/leucovorin/5-fluorouracil), gemcitabine/nab-paclitaxel, capecitabine, pazopanib, pembrolizumab, paclitaxel, nivolumab, gemcitabine/carboplatin | PDGFRB | Direct | 1 | ||||||||
| pexidartinib, durvalumab | PDGFRB | Direct | 1 | ||||||||
| radiation therapy, temozolomide, sorafenib | PDGFRB | Direct | 1 | ||||||||
| regorafenib, lomustine | PDGFRB | Direct | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | PDGFRB | Direct | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | PDGFRB | Direct | 1 | ||||||||
| regorafenib, temozolomide | PDGFRB | Direct | 1 | ||||||||
| ryz101, everolimus, sunitinib, octreotide, lanreotide | PDGFRB | Direct | 1 | ||||||||
| sorafenib | PDGFRB | Direct | yes | 1 | |||||||
| sorafenib, erlotinb | PDGFRB | Direct | 1 | ||||||||
| sorafenib, rad001 | PDGFRB | Direct | 1 | ||||||||
| sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide | PDGFRB | Direct | 1 | ||||||||
| sunitinib, placebo | PDGFRB | Direct | 1 | ||||||||
| sunitinib, radiation | PDGFRB | Direct | 1 | ||||||||
| sunitinib, sunitinib | PDGFRB | Direct | 1 | ||||||||
| temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 | PDGFRB | Direct | 1 | ||||||||
| tivozanib | PDGFRB | Direct | 1 | ||||||||
| topotecan, pazopanib | PDGFRB | Direct | 1 | ||||||||
| topotecan, sorafenib | PDGFRB | Direct | 1 | ||||||||
| trc 105, sorafenib | PDGFRB | Direct | 1 | ||||||||
| vemurafenib, sorafenib | PDGFRB | Direct | 1 | ||||||||
| axitinib | PDGFRB | Direct | yes | 0 | |||||||
| becaplermin | PDGFRB | Direct | yes | 0 | |||||||
| dasatinib | PDGFRB | Direct | yes | 0 | |||||||
| imatinib | PDGFRB | Direct | yes | 0 | |||||||
| imatinib mesylate | PDGFRB | Direct | yes | 0 | |||||||
| midostaurin | PDGFRB | Direct | yes | 0 | |||||||
| nintedanib esylate | PDGFRB | Direct | yes | 0 | |||||||
| pazopanib hydrochloride | PDGFRB | Direct | yes | 0 | |||||||
| sorafenib tosylate | PDGFRB | Direct | yes | 0 | |||||||
| sunitinib malate | PDGFRB | Direct | yes | 0 | |||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| binimetinib and encorafenib | BRAF | SSL via BRAF | yes | 1 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| sunitinib | KDR | SSL via KDR | yes | 5 | |||||||
| sunitinib | KIT | SSL via KIT | yes | 5 | |||||||
| sunitinib | PDGFRA | SSL via PDGFRA | yes | 5 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | ABL1 | SSL via ABL1 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | FGFR1 | SSL via FGFR1 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | KDR | SSL via KDR | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | KIT | SSL via KIT | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | PDGFRA | SSL via PDGFRA | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | RAF1 | SSL via RAF1 | 4 | ||||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | RET | SSL via RET | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | ABL1 | SSL via ABL1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | FGFR1 | SSL via FGFR1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | KDR | SSL via KDR | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | KIT | SSL via KIT | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | NTRK1 | SSL via NTRK1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | PDGFRA | SSL via PDGFRA | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | RAF1 | SSL via RAF1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | RET | SSL via RET | 4 | ||||||||
| ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine | KDR | SSL via KDR | 3 |